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Abstract
M. Joglekar, J. Ware, T. K. Gartner. FeCl3-induced thrombus formation in murine
inferior vena cava requires platelets, platelet receptor GPIb-IX and von Willebrand
factor. XXII Congress July 11-16, 2009. International Society on Thrombosis and
Haemostasis. Major Professor: T. Kent Gartner, PhD.
Venous thromboembolism (VTE) is the leading cause of death from
cardiovascular disease. Despite the importance of the glycoprotein (GP) Ib-IX/von
Willebrand factor (VWF) axis in arterial thrombosis, its requirement in venous, not
venule thrombosis has not been tested. We evaluated FeCl3-induced thrombus formation
in inferior vena cava (IVC) of mice. We first established FeCl3 injury conditions (20%
FeCl3, 10 minutes) requiring platelets for IVC occlusion as confirmed by a lack of
occlusion in severely thrombocytopenic (less than 23% circulating platelet count) mice
(n=7) and stable occlusion in control animals.

Using similar injury conditions, no IVC occlusion was observed using platelet
GPIbα-deficient animals (n=6), a model of human Bernard-Soulier syndrome (BSS).
Transgenic IL-4R/GPIbα mice were studied to determine if the absence of IVC occlusion
in the mouse model of BSS was caused by extracellular GPIbα deficiency or by other
platelet abnormalities associated with BSS phenotype. IL-4R/GPIbα mice lack murine
GPIbα, but express a transgenic fusion protein compound of an extracellular domains of
human IL-4 receptor fused to the transmembrane and cytoplasmic domains of human
GPIbα ; an ameliorated form of mouse BSS lacking macrothrombocytopenia. No
occlusion was observed in the IVC of IL-4R/GPIbα mice (n=8), just as observed with the
murine model of BSS. VWF-deficient mice were also studied and failed to occlude in
response to FeCl3 treatment (n=7).

v

These data establish experimental conditions for FeCl3-induced thrombus
formation in the IVC that is platelet, platelet receptor GPIbα and VWF-dependent despite
the low venous flow rate in the IVC. Also unlike venules, thrombus formation in IVC’s is
GPIb-IX dependent, and fibronectin cannot substitute for VWF in IVC’s as it can in
arterioles.
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CHAPTER 1: INTRODUCTION
Venous thromboembolism (deep vein thrombosis (DVT) and/or pulmonary
embolism, PE) is a leading cause of morbidity and mortality in the United States. VTE
causes about 300,000 deaths annually. VTE is a multifactorial disease with both
environmental and genetic causal factors [1]. The frequency of VTE increases with
increasing age. Therefore the importance of VTE increases as the population ages. The
pathogenesis of VTE is poorly understood. This in turn has increased the importance of
studying the basis of deep vein thrombosis.
Thrombus formation occurs by different mechanisms in arteries and veins.
Thrombus formation in arteries involves platelet interactions with the vessel wall and is
shear dependent [2]. Following vascular injury, collagen in the subendothelium is
exposed and subsequently plasma von Willebrand factor (VWF) binds to the collagen and
is immobilized on the subendothelium. The initial platelet tethering to the injured site is
mediated by the interaction of immobilized VWF with platelet receptor GPIbα [3].
Downstream signaling through GPIb results in thromboxane A2 (TxA2) production
followed by platelet dense granule secretion which releases ADP. Both TxA2 and ADP
can activate the integrin αIIbβ3 which mediates platelet aggregation and spreading [4].
ADP activates the nearby platelets thereby facilitating the platelet-platelet interactions
and increasing the recruitment of more platelets to the site of injury.
Venous circulation operates at low shear (low shear rate, e.g. 50 s-1 – 100 s-1) and
it is generally believed that thrombus formation in this bed is less dependent on platelets
or shear-dependent interactions with the vessel walls. VTE is thought to arise from
changes in the vessel due to stasis [5], inflammation of the vein wall [6], or coagulation
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and fibrinolytic abnormalities. In fact, some scientists consider inflammation and/or
coagulation to be the initial steps for thrombus formation in veins. Thrombus formation
in venules ( shear rate- 150 sec-1 – 200 sec-1 ) has been studied and is shown to be VWF
dependent but does not absolutely require GPIb [7].Compared to arteries, shear rates in
veins are much lower [8]. Shear rates have a profound effect on the thrombus formation.
Although in vitro studies have shown that VWF can mediate platelet-vessel wall
interactions even at low shear rates [9], the contribution of platelets, GPIbα and VWF in
the venous circulation (not venules) has not been characterized. Thus, the objective of
this project was to characterize the requirement of platelets, GPIbα and VWF for in vivo
venous thrombus formation in mice in reponse to FeCl3- induced injury.
To study the contribution of platelet-vessel wall interactions in VTE thrombus
formation in murine inferior vena cava (IVC) was studied in response to ferric chlorideinduced injury. The results of this study will establish whether or not thrombus formation
under conditions of venous shear rate can be dependent on platelets, platelet receptor
GPIb-IX-V and VWF.
1.1. Deep Vein Thrombosis
There are two types of veins in the leg; superficial veins and the deep veins. The
superficial veins lie just below the skin and the deep veins are located deep within the
muscles. In deep vein thrombosis, a blood clot forms in the deep veins of leg. The clot
can be formed due to vascular damage or slow or no blood flow (stasis). Sometimes the
clot breaks off and travels to the lungs (pulmonary embolism) via venous circulatory
system. This process is known as venous thromboembolism (VTE). Risk factors of DVT
are age, surgery, trauma, and immobility [1]. People traveling long distances are at risk of
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DVT due to immobility in automobiles and aircrafts. The symptoms of DVT are related
in part to the limited blood flow to the heart, and include pain in the leg, swelling due to
inflammation, warmth and redness.
1.2. Overview of Blood Coagulation/ Haemostasis
Blood coagulation or haemostasis is a complex process that regulates and stops
bleeding at the site of vascular injury. Coagulation process depends upon two pathways:
Tissue factor pathway (extrinsic) and contact activation (intrinsic) pathway.
Conventionally it is accepted that the initiation of the coagulation pathway is triggered by
the extrinsic pathway and the intrinsic pathway amplifies the cascade. These two
pathways ultimately lead to fibrin formation (common pathway) that helps to stop
bleeding by forming a clot consisting of fibrin and platelets (Fig.1). The two pathways
involve activation of an inactive enzyme or zymogen (protease) to its active form which
further catalyzes the next reaction in the cascade. The end result is formation of a fibrin
mesh which helps to hold platelet plug together.
1.2.1. Tissue factor pathway (extrinsic)
Tissue factor pathway is initiated upon vascular injury/ trauma. Upon the vascular
injury, circulating FVII (inactive) comes in contact with the tissue factor (TF) expressed
by vascular smooth muscle cells. Under normal conditions, the TF expressed by the
vascular smooth muscle cells is masked or separated by the endothelial cells, but after the
endothelial cell layer is damaged due to injury, the TF is exposed to the flowing blood
and binds to the circulating FVII. Binding of the TF to the FVII forms TF:FVII complex
(active). Activated TF:FVII complex activates FIX and FX. Constitutive activation of the
TF:FVII complex can prove to be dangerous and thus immediately after the TF:FVII
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complex activates FX, the TF:FVII complex is inhibited by the tissue factor pathway
inhibitor (TFPI). The activated FX (FXa) along with its cofactor FVa forms the
prothrombinase complex. Prothrombinase complex further converts prothrombin to
thrombin. Further thrombin activates FV and FVIII. FVIIIa is a cofactor for activation of
FIX and so the cycle continues.
1.2.2. Contact activation (intrinsic) pathway
This pathway starts with formation of the primary complex on the collagen by a
protein called ‘high molecular weight kininogen (HMWK), prekallikrein and FXII
(Hageman factor). In this pathway, prekallikrein is converted to kallikrein and FXII is
converted to its active form (FXIIa). FXIIa activates FXI (FXIa). FXIa in turn activates
FIX. FIXa with its cofactor FVIIIa, activates FX to FXa. This explains the amplifying
characteristic of the intrinsic pathway. The extrinsic and intrinsic pathways converge at
this point into the common pathway.
1.2.3. Common pathway
In this pathway, the thrombin generated by the intrinsic and extrinsic pathway
converts fibrinogen to fibrin, which is the building block of the haemostatic plug or a
clot.
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Fig.1: Coagulation cascade (normal haemostasis)

1.3. Platelets
Platelets are a critical component of the blood because of their fundamental role
in hemostasis and thrombosis. Platelets are anucleate hematopoietic cells. Human
platelets are 2.0-5.0 µm in diameter and 0.5 µm in thickness. Normal range of platelet
number in blood is 150-400 Χ 109 per liter [10]. Platelets function as cellular “zymogens”
dedicated to immediate participation in hemostasis at the sites of vascular injury.
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1.3.1 Structure
Platelet structure includes a plasma membrane, the cytoskeleton, and the
cytoplasm [10].
1.3.1a Plasma membrane
The plasma membrane of the platelets consists of a glycocalyx. The exterior
surface is a very dynamic structure which serves as the site for the first contact in
response to the changes in vascular system. The glycocalyx is mainly composed of the
glycoprotein receptors which are necessary for platelet adhesion to vascular surface and
to promote platelet aggregation and interaction with the other blood components. The
plasma membrane is made up of the lipid bilayer.
1.3.1b Cytoskeleton
The cytoskeleton consists of microtubules and microfilaments. The microtubules
are present in bundles ranging from 3 to 24 and are present very close to the plasma
membrane. The major protein constituent of microtubules is tubulin. Microfilaments are
made up of globular protein called actin. These filaments play a vital role in platelet
physiology. Microfilaments are present near both the plasma membrane and are the major
constituent of the cytoplasmic cytoskeleton. The microfilaments associated with the
plasma membrane serve as matrix on which the organelles are suspended. The
cytoskeleton helps the secretion of the contents from the α-granules and dense bodies to
the exterior after the platelet activation.
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1.3.1c Cytoplasm
Platelet cytoplasm contains α-granules, dense bodies, lysosomes, mitochondria.
α-granules- There are 40 to 80 α-granules per platelet. They are round to oval shaped,
surrounded by a membrane and are about 200 to 500 nm in diameter. The granules
contain more than two dozen different proteins which play a role in hemostasis,
thrombosis and wound healing such as adhesive proteins, chemokines, cytokines,
coagulation factors, angiogenic regulatory proteins and fibrinolytic proteins etc.
Dense bodies- Dense bodies are smaller and less numerous than the α-granules. Dense
bodies are spherical and covered with an enclosing membrane. Some dense bodies can
have whiplike extensions. On an average, there are 4-8 dense bodies in a platelet. Dense
bodies are rich in adenine nucleotides such as ATP and ADP, serotonin, calcium,
magnesium and pyrophosphates.
Mitochondria- There are very few mitochondria present in a platelet. These are very
simple structurally and are the sites of oxidation in the platelets.
Lysosomes- Human platelets have few lysosomes (minimum 0 to 1, maximum 3). They
have 13 acid hydrolases and cathepsin D and E and CD36 (a lysosomal membrane
protein). The function of platelet lysosomes is not clear but they release their contents
after platelet activation. Platelet lysosomes do not engulf bacteria as do phagocytes so
they are considered as vestigal organelles with no clear function in platelets.
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1.3. 2.Platelet Receptor Glycoprotein IB-IX-V
The glycoprotein Ib-IX-V complex is an important platelet membrane adhesion
receptor that participates in both haemostasis and thrombosis. As shown in figure 2, the
GPIb-IX complex is made up of the following four different gene products: GPIbα (~ 135
kDa), which is linked to GPIbβ (~25 kDa) by disulfide bonds, GPIX (~22 kDa) and GPV
(~82 kDa). The GPIX and GPV components are attached to the GPIb by non-covalent
interactions. These four subunits make the intact GPIb-IX-V complex as shown in figure
2. This complex is expressed on the platelet surface in the ratio of 2:2:2:1 for GPIbα:
GPIbβ: GPIX: GPV. About 25,000 GPIb-IX-V complexes are constitutively expressed on
the platelet surface [3]. In humans, GPIb, IX, and V are type I membrane spanning
subunit having a N-terminal ligand binding domain, a transmembrane region and
cytoplasmic tail as shown in figure 2. The N- terminal domain of the GPIbα contains the
VWF binding domain.

Fig. 2: Glycoprotein Ib-IX-V complex
(Modified from: journals.prous.com/journals/servlet/xmlxsl/pk... )
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1.3.2a Functions of GPIb-IX-V
The main functions of the platelet receptor GPIb-IX-V complex are as follows:
1.

Regulation of platelet adhesion to the sub-endothelial layer and

leukocytes.
2.

Assemble/procoagulant activity on activated platelets.

3.

Initiate outside-in signaling that activates platelets and platelet αIIbβIII

resulting in platelet aggregate formation at the site of platelet adhesion to the
damaged endothelium. (Topographical interactions) [11].
1.3.3. Ligands of GPIb-IX-V complex
VWF is the major ligand for the receptor GPIb. Amongst the other ligands
includes thrombospondin (TSP), thrombin and P-selectin. There are a variety of nonphysiological ligands for this receptor such as snake venoms toxins and bacteria [12].
1.3.3.1 von Willebrand factor (major ligand)
Interaction of soluble (that which circulates in the blood) VWF with its receptor
GPIb is shear dependent. At all arterial shear rates, the GPIbα-VWF interaction is
required for platelet adhesion to the damaged vasular surface [13]. The interaction of
GPIbα and VWF has been studied by crystallography. VWF binds to the N-terminal
ligand binding region of GPIbα by its A1 domain [14]. GPIbα residues have a direct
contact with the VWF A1 domain and are clustered toward the N-terminal and Cterminal ends of the ligand binding region [12]. VWF is the major ligand of glycoprotein
receptor Ibα. Binding of VWF to its receptor GPIbα is essential, as it elicits the initial
step for the platelets to become stationary on the injured vascular wall and thus for the
thrombus growth. Binding of VWF to GPIbα also triggers signaling events that lead to
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platelet activation, as well as cytoskeletal changes that regulate platelet spreading, shape
change, secretion and aggregation. Under normal circumstances, soluble VWF does not
bind stably to GPIbα on platelets suspension [12]. Normal interaction of GPIbα with
VWF requires a trigger which can be pathological shear stress, immobilization of VWF
on collagen or other subendothelial components. After VWF-mediated adhesion of
platelets to the damaged endothelium, secreted VWF can bind to active αIIbβ3 in the
growing aggregate thereby facilitating hemostasis or thrombus formation [12].
1.3.3.2 Thrombospondin
Thrombospondin-1(TSP) is a recently identified ligand for GPIb-IX-V. TSP binds
GPIb-IX-V at high shear rate and is able to support platelet adhesion in absence of VWF
[15].
1.3.3.3 Thrombin
Thrombin binds to the α-subunit of GPIb at the Tyr276 residue, an interaction
important for normal physiological hemostasis and thrombosis. In vivo thrombus
formation was studied for both laser induced injury mouse model and FeCl3 induced
injury model using the transgenic mice expressing the normal human GPIbα (hTgWT)
subunit and a mutant human GPIbα containing a Phe substitution for the Tyr276
(hTgY276F). Delayed thrombus formation in the mutant mice (hTgY276F) in the FeCl3
induced injury and less stable thrombus in laser induced injury demonstrates the
physiological importance of this interaction [16].
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1.3.3.4 P-selectin
P-selectin is a type I transmembrane protein which is expressed on the activated
endothelial cells. It is present in both the endothelial cells (Weibel-Palade bodies) and in
the α-granules of platelets. P-selectin recruits leukocytes (through its P-selectin
glycoprotein ligand-1 [PSGL-1] receptor) to the activated endothelial cells in an
inflammatory response. Studies have shown that, like leukocytes, P-selectin can also bind
to the platelet GPIbα. Adhesion studies carried out in the CHO (Chinese Hamster Ovary)
cells expressing P-selectin show that these cells adhere to the immobilized GPIbα
(glycocalicin) in a P-selectin dependent manner [17]. Thus it has been shown that the
platelet GPIbα and P-selectin interactions may have a potential role in pathological
conditions.
1.3.3.5 αMβ2
αMβ2 is a leukocyte integrin and it is also known to be a ligand for platelet
receptor GPIbα. The αMβ2-GPIbα interaction is required for adhesion of leukocytes to
the growing thrombus at the injured vascular bed [18]. The αMβ2-GPIbα interaction
also facilitates physiological clearance of cold stored (<15º C) platelets. This clearing is
due to the cold induced clustering of GPIbα which leads to clearance of platelets by
phagocytic liver macrophages or Kupffer cells [19].
1.3.3.6 Non-physiological GPIbα ligands
Bacteria can bind to the platelet specific receptor GPIbα. Binding of bacteria to
the receptor can be of physiological significance and can increase the risk of thrombosis.
GPIbα has high amount of sialomucin. Some bacteria recognize the sialic acid by their
cell wall proteins, e.g. Streptococcus gordonii. Some bacteria such as Staphylococcus
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aureus, bind the GPIbα receptor by forming bridging interactions between GPIbα and
VWF. Other bacteria bind directly to the N-terminal domain of GPIbα [12].
Snake venoms are also one of the non-physiological ligands of GPIbα. Snake
venoms are complex mixtures of active proteins and peptides. Based on their
protein/peptide sequence, they are classified as serine proteases, metalloproteinases, Ctype lectins, disintegrins or phospholipases. They take part in hemostasis by either
activating or inhibiting platelet functions, coagulant factor functions or disrupting the
endothelial cells (e.g. metalloproteinases in the Crotalidae or Viperidae degrades the
blood vessel extracellular matrix [ECM] thus affecting the haemostasis or Rhodostomin
[a disintegrin] inhibits steps in angiogenesis and also can induce endothelial cell
apoptosis.)The snake venoms activate platelets by activating protease receptors, or by
binding or degrading VWF and platelet receptors or by altering the TxA2 production
[20].
1.3.4. GPIb-IX-V Signaling
Thrombus formation in vessels with high shear rates such as in arteries is
dependent on the platelet adhesion receptor GPIb-IX-V [2, 3 and 4]. Upon vascular
injury, the collagen in the subendothelium is exposed and circulating VWF binds to the
collagen. VWF-GPIb initial interaction triggers GPIb dependent signaling (Fig.3) which
results in TxA2 production. This signaling is initiated by Lyn (a tyrosine kinase), Syk (a
cytoplasmic tyrosine kinase), SLP-76 (Src homology 2 (SH2) domain containing
leukocyte protein76 (SLP-76), Phosphatidylinositol 3-kinase (PI3K), Bruton tyrosine
kinase (BtK), Phospholipase Cγ2 (PLCγ2) and protein kinase C (PKC) which ultimately
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activates receptor integrin αIIbβ3 which leads to platelet aggregation and secretion
(Fig.3).

Fig.3: GPIb-IX-V Signaling and platelet adhesion
Source: J. Liu, M. Joglekar, J. Ware, M. E. C. Fitzgerald, C.A. Lowell, M. C. Berndt and
T. K. Gartner. Evaluation of physiological significance of botrocetin/von Willebrand
factor in vitro signaling. 2008; 6: 1915-1922.

Thus the VWF-GPIb initial interaction induces a cascade of events including
protein phosphorylation, calcium elevation, phospholipase activation, TxA2 production
and ADP secretion. These events lead to platelet aggregation that can be a part of normal
hemostasis or thrombus growth at the site of injury [4].
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Fig.4: GPIbα signaling resulting in platelet activation and aggregation.
Source: J. Liu, T.I. Pestina, M.C. Berndt, S. A. Steward, C. W. Jackson and T. K.
Gartner. The roles of ADP and TxA2 in botrocetin/VWF-induced aggregation of washed
platelets. J Thromb Haemost. 2004; 2: 2213- 2222.

Fig.4, shows in detail the events induced by GPIbα- initiated signaling.
Activation of GPIbα leads to thromboxane A2 (TxA2) production and secretion. TxA2
then binds to its G-protein coupled receptor which functions through Gαq activation. Gαq
recruits PLCβ which in turn produces inositol- trisphosphate (IP3) and diacyl glycerol
(DAG). IP3 and DAG mobilize the intraplatelet Ca2+ which in turn activates protein
kinase C (PKC). PKC triggers dense granule secretion. ADP is released along with the
other contents of dense granules. ADP binds to G- protein coupled P2Y1 and P2Y12
receptors which function through Gαq and Gαi respectively. The signaling through Gαq
further amplifies the dense granule secretion and the signaling through Gαi promotes α-
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granule secretion by inhibiting cAMP production. Fibrinogen present in the α-granules is
released and binds to its receptor, αIIbβ3. These events lead to platelet aggregation [4].
1.4. von Willebrand Factor (VWF)
VWF is a large multimeric adhesive glycoprotein. It is present in plasma,
endothelial cells (Weibel Palade bodies), megakaryotes, platelet α-granules and in
connective tissue. It is secreted through constitutive and regulatory (secretory) pathways.
It is constitutively secreted from the Weibel Palade bodies in the endothelial cells. It has
been shown that the VWF present in plasma is structurally different from that present in
the platelet α-granules. The platelet VWF is larger than the one present in plasma. This
structural difference can play a specific role in normal haemostasis [21]. A mature VWF
molecule is about residues or 275 kDa. It consists of linear sequence of modular domains
as designated: D′-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2. The VWF in Weibel Palade
bodies in endothelial cells is ultra-large VWF and is hyperadhesive. The ultra-large VWF
is processed to smaller, less adhesive forms of VWF by proteolysis by (A Disintigrin and
Metalloprotease with Thrombospondin motif) called ADAMTS13 [12]. VWF plays a role
in normal haemostasis as it promotes platelet adhesion to the site of vascular injury and
platelet-platelet cohesion for the thrombus growth. It is also a carrier for coagulation
Factor VIII in plasma and protects it form proteolysis thus facilitating thrombin
generation. The smaller VWF (multimers) are secreted in the circulation from large
complexes of protein at the time of or after secretion from endothelial cells [12]. VWF
acts as a major ligand for the platelet specific receptors GPIb-IX-V and αIIbβIII as shown
in Fig.3. VWF/GPIbα interaction mediates platelet tethering to the subendothelium in
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arteries, arterioles and venules [22], but the requirement for VWF and GPIbα in stable
thrombus formation in veins has not been reported.
1.5. Research Approach
A mouse model of ferric chloride-induced injury to the inferior vena cava (IVC)
was used to study thrombus formation under venous shear rates. The requirements of
platelets, the platelet specific receptor GPIbα and its ligand VWF were characterized
using ‘knock-out’ mice. KO mice are genetically engineered mice in which a particular
structural gene for a specific protein is subjected to a major structural alteration that
results in permanent loss of the normal gene product. KO mice lacking the specific
protein are used to evaluate the importance of that protein in signaling.
Lack of thrombus formation in the knockout mice in response to FeCl3-induced injury
shows the requirement for the missing function for a stable thrombus formation.
1.6. Objective
The immediate objective of this project is to evaluate the requirements for
platelets, the platelet specific glycoprotein Ibα receptor and VWF in FeCl3-induced stable
thrombus formation in the mouse inferior vena cava.
This objective will be accomplished by completing following specific aims:
1. Evaluate ferric chloride-induced thrombus formation in the IVC in mice with
thrombocytopenia (22 % of the normal platelet count) induced by treatment with a
mixture of rat anti-mouse GPIb monoclonal antibodies that elicit a rapid depletion
of host animal’s platelets. Assuming that platelets are required for stable thrombus
formation in IVC, Aim 2 will be completed, if not, Aim 4 will be completed in
absence of completion of Aim 2 and 3.

16

2. Evaluate ferric chloride-induced stable thrombus formation in GPIb KO mice.
The platelets produced in these mice lack GPIb, resulting in a condition known in
humans as Bernard Soulier syndrome (BSS). The mice suffering from BSS
produce abnormal platelets as a consequence of lacking GPIb. Assuming that
GPIb is required for ferric chloride-induced stable thrombus formation in the IVC,
Aim 3 will be completed.
3. Evaluate FeCl3-induced stable thrombus formation in transgenic mice which lack
murine GPIb, but express a chimeric form of human GPIb. The chimeric protein
is designed to eliminate the extracellular domain of GPIb, without disrupting the
normal non-stimulated function of the cytoplasmic domain of GPIb. Expression
of transgenic GPIb mice ameliorates the abnormalities associated with the GPIb
deficiency (BSS).
4. Evaluate FeCl3-induced stable thrombus formation in VWF KO mice. These mice
very closely mimic the severe or type 3 human von Willebrand disease. Type 3
von Willebrand disease is characterized by absence of VWF in plasma, platelets,
endothelial cells and subendothelium. Therefore these mice exhibit defects in
hemostasis and show highly prolonged bleeding times.
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CHAPTER 2: MATERIAL AND METHODS
2.1. Animals
Mice deficient in the platelet receptor glycoprotein Ibα, and the IL-4R/GPIb
transgenic mice were obtained from Dr. Jerry Ware’s laboratory at the University of
Arkansas for Medical Sciences (Little Rock, AR) [23], [24]. The IL-4R/GPIbα-tg mice
lack murine GPIbα. They express the extracellular domain of human IL-4 receptor fused
with the transmembrane and cytoplasmic domains of human GPIbα. The von Willebrand
factor KO mice [25] were bred in our animal facility (University of Memphis) from
breeding stock obtained from Jackson Laboratory, Maine. Heterozygotes of these KO
strain have been backcrossed with C57Bl/6 mice for at least eight generations.
2.2. Ferric chloride-induced inferior vena cava injury
Mice were anesthetized using isofluorane (Baxter International Inc, Deerfield IL).
The intact IVC was dissected free from surrounding tissue and placed on a paper strip
covered with adhesive tape (13×3 mm), for support (Fig.5). Injury was induced by topical
application of a longitudinally folded strip of Whatman No. 1 filter paper (14×3mm)
saturated with 20% FeCl3 [26, 27] (J.T Baker Co; NJ) for 10 minutes at room
temperature. Then the tissue was rinsed with physiological saline to remove FeCl3. Blood
flow was monitored using a laser Doppler system with a pencil probe. Monitoring of
blood flow lasted for 45 minutes starting at the time of the application of FeCl3.
Occlusion was defined as a decrease of blood flow of 75% or more for at least 3 minutes
[28].
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Fig.5: Ferric chloride-induced
induced inferior vena cava injury. (The arrow indicates the inferior
vena cava separated on the paper strip covered with adhesive tape).

2.2.1 Why ferric chloride induced injury model
Ferric chloride (FeCl3) is often used to induce injury in mice and other animals.
The murine model for thrombus formation in response to fer
ferric
ric chloride induced injury is
well characterized [29].. FeCl3 induces injury to the vessel by oxidizing the vessel and
rupturing the endothelial layer and thus exposing collagen [27]. Furthermore, thrombus
formation in response to FeCl3 in the carotid artery is GPIbα-dependent [30, 31].
31] Lack of
stable thrombus formation was observed in mice lacking the extracellular domain of the
platelet receptor GPIbα
α (which is the major ligand binding domain) after treating the
carotid artery with 10% FeCl3 [28]. These data demonstrate that stable thrombus
formation in response to FeCl3 induced injury is GPIbα dependent in the carotid arteries.
Therefore FeCl3-induced
induced injury model was an appropriate model to characterize the
requirement for platelets,
atelets, the platelet specific receptor GPIb
GPIbα and VWF in thrombus
formation under venous shear rates.
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2.2.2 Why 20% ferric chloride
Stable occlusion in the murine carotid artery occurs reproducibly in response to
treatment with 10% FeCl3 for 3 minutes, with the mean time of occlusion of ~ 5.0
minutes [28] (Fig.6A). Therefore, initially exposure to 10% ferric chloride for 3 minutes
was used for the IVC studies. This treatment procedure did not elicit stable occlusive
thrombi in the IVC. None of the mice treated with 10% ferric chloride solution for 3
minutes showed occlusion (Fig.6B). Next, the time for exposure was increased from 3
minutes to 10 minutes keeping the concentration of FeCl3 the same (10%). The increase
in the exposure time did not result in stable thrombus formation (Fig.7A, B). Therefore,
the concentration of ferric chloride was increased to 20% keeping the time for exposure
as 10 minutes. This concentration of ferric chloride resulted in complete and stable
occlusion of the IVC (Fig.8). The results were reproducible.
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Fig.6: Changes in blood flow in FeCl3 treated carotid artery (A) and inferior vena
cava (B).
(A): A 3 minutes treatment with 10% FeCl3 causes stable thrombus formation in a WT
mouse within 5 minutes.
(B): 10% FeCl3 treatment for 3 minutes does not occlude the IVC.

Fig.7A&B: Treatment of 10% FeCl3 for 10 minutes did not occlude the IVC.
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Fig. 8: Treatment of 20% FeCl3 to the IVC of WT mice for 10 minutes caused complete
occlusion.

Therefore treatment of the IVC with 20% ferric chloride treatment for 10 minutes
was used for the following study. Our studies showed that 10% ferric chloride was
sufficient to elicit the formation of stable thrombi in arteries, but was not sufficient to
elicit stable thrombus formation in IVC. The reason(s) for this difference in response
is/are not understood.
2.2.3 Artery vs. Vein
A comparison of the structural features of arteries and veins is presented because,
it is considered that mechanism of thrombus formation in veins is essentially different
from that in arteries. Also there is a physiological difference in between these two types
of vessels (Fig.9).
The walls of arteries and veins are made up of three layers which surround the lumen:
a. Tunica interna/intima- This is the innermost layer which is made up of endothelial
cells.
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b. Tunica media- This is the middle layer made up of circularly arranged smooth
muscle cells and sheets of elastin. This layer is generally thicker in arteries than in
veins.
c. Tunica externa- This is the external layer composed of loosely meshed collagen
fibres. These fibers protect the vessel and help in anchoring the vessels to the
surrounding structures.
These three layers of the vessels differ in the diameter and the thickness according to the
type of blood vessel (arteries, arterioles, veins, venules). The shear rates in arteries and
veins are different (Table 1). Veins have thinner elastic fiber and smooth muscle layers
than arteries and have thin smooth muscle layer [30].

Table 1 Difference in arteries and veins [32]
Artery

Vein

(Resistance Vessels)

(Capacitance vessels)

Thick smooth muscle layer ( tunica media)

Thin smooth muscle layer (tunica media)

Small diameter/lumen

Large lumen/diameter

Elastic artery-

Vein- 5.0 mm

1.5 cm

Muscular artery- 6.0 mm
High shear rates (~ 1500 sec-1)

Low shear rates (50-100 sec-1)

Muscular and thick walls; resistant to

Veins are much flexible in nature

stretching
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Fig.9: Cross-section
section of IVC showing structural differences between an artery (AA(AA
abdominal aorta) and vein (IVC
(IVC- inferior vena cava). The section was stained with
Masson’s trichrome stain. ((Magnification: 10 X)

2.3. Laser flow Blood Perfusion Monitor (BMP2)
Thee laser flow blood perfusion monitor uses laser doppler technology. A low
power beam of laser light is delivered to the tissue via a fiber optic pencil probe. The
optic fibers in the pencil probe collect the light signals carrying information. The probe is
connected to the blood perfusion monitor which is in turn is connected to the computer.
Graphical representation of the blood flow is obtained from the computer. The final
results are local blood flow rates.
2.4. Platelet depletion
An Fc receptor-independent
independent decrease in mouse platelets was elicited by the
injection of a mixture of rat anti
anti-mouse
mouse GPIb monoclonal antibodies (mabs)
(mab into the tail
veins of mice [33].. Each isofluorane anesthetized mouse was dissected to expose the
IVC prior to treatment (to prevent excess bleeding) with the anti-mouse
mouse GPIb mabs
(1µg/g of the anti-GPIbα
α antibody; Emfret Analytics, Germany). Monoclonal antibody
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(mab) was injected into a tail vein. Less than 23% of the platelets remained 15 minutes
after injection of the antibodies (data not shown). FeCl3 treatment of the exposed IVC
was initiated 15 minutes after injection of the anti-GPIb antibodies. As a negative control
for platelet depletion, 1µg/g of non-immune rat IgG (Emfret Analytics, Germany) was
injected in the tail vein after exposing the IVC.
2.5. Histological studies
For the histological studies, the tissue (IVC) was fixed in 16 % paraformaldehyde
for 24 hours at 4ºC. The tissue was further processed by dehydrating the samples in
increasing concentrations of ethanol (70% for 30 min, 95% 2×30 min, absolute ethanol
3×30 min). The tissue was then cleared with xylene 3×30 min and infiltrated with
paraffin for one hour and then embedded in paraffin blocks. Sections of tissues (5 mm
thickness) were treated with Diffquick stain. This treatment stains platelets in a violet to
purple color.
2.6 Immunohistological studies
Immunohistochemical studies were performed on the 0.5 mm thick IVC sections
(control and IVC treated with 20% FeCl3 for 10 minutes) as directed in the protocol for
Vectastain ABC-Alkaline phosphatase Kit (Vector Laboratories, Inc. 30 Ingold Road,
Burlingame, CA, USA). An anti- GPIbα antibody (Emfret Analytics, Germany) was used
as a primary antibody with (1:1000) dilution. The secondary antibody (biotinylated) was
used with (1:200) dilution. The staining procedure stained platelets red.
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2.7. Statistical Analysis
Statistical analyses were done using Chi-square test from Microsoft Office Exel,
this involved comparison of two groups. Values of p < 0.05 are considered statistically
significant.
2.8. Box Plots for the murine blood flow analysis
The box plots for the murine blood flow analysis were done using SPSS
(Statistical Package for Social Sciences). SPSS was used for both control and KO mice.
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CHAPTER 3: RESULTS
3.1. FeCl3 treatment of the inferior vena cava causes platelet dependent stable
thrombus formation.
Stable thrombus formation can be induced in a murine carotid artery (CA) by
treatment with FeCl3 [24, 28, 29, 34]. FeCl3-induced stable thrombus formation in the CA
is GPIb and therefore platelet dependent [2, 24, 29]. Occlusion of blood flow as a
consequence of FeCl3 treatment was the end point of those studies. Platelet rich thrombi
were shown to be the basis of occlusion of blood flow in those studies that included
characterization of the basis of occlusion [25, 28]. Although a variety of studies
characterizing the role of coagulation factors and their inhibitors in FeCl3-induced
thrombus formation in mouse IVC have been described [35-37], occlusion of blood flow
in response to thrombus formation was not monitored. Instead, the weights of thrombi
were measured.
As a prelude to investigating the role of GPIb in stable thrombus formation in the
IVC, the efficacy FeCl3 treatment as an inducer of stable, platelet-dependent thrombus
formation in the IVC of wild type mice was characterized. In this study, the platelet
requirement for thrombus formation was evaluated by monitoring blood flow following
FeCl3 treatment of the IVC in the presence and absence of a mixture of purified rat antimouse GPIb mabs [31]. Treatment of the circulating platelets with a mixture of
appropriate divalent rat monoclonal anti-mouse GPIb IgG causes rapid, FcR-chain
independent depletion of the platelets [31]. For our experiments, the mixture of IgG was
injected into a tail vein of each anesthetized mouse after exposure of the IVC by
dissection, and 15 minutes before treatment of the exposed IVC with 20% FeCl3. The
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control treatment was injection of nonimmune rat IgG into the tail veins of mice
subsequently treated with FeCl3. In contrast to the control treatment, treatment of the
mice with the anti-GPIb mabs resulted in depletion of at least 77% of the platelets (data
not shown) by the end of blood flow monitoring period. FeCl3 treatment of the IVC
resulted in occlusion of blood flow in all the control animals. Five of the 7 controls
treated with nonimmune IgG underwent total occlusion, 2 of the thrombi that caused total
occlusion subsequently embolized prior to the end of the observation period. Two out of
the 7 FeCl3 treated control veins underwent stable partial occlusion; that is, total
occlusion and embolus formation did not occur during the monitoring period. In contrast,
the FeCl3-treated inferior vena cavae (n=7) of the mice containing the rat anti-GPIb mabs
did not occlude (Fig. 10A). Occlusion in the control animals (Fig.10A) was caused by
platelet-rich thrombi (Fig.14B) consistent with the platelet requirement for thrombus
formation.
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Fig.10A: 20% FeCl3-induced IVC injury to the WT mice treated with Rat IgG (top panel)
and anti-GPIb mab (bottom panel). (Blood flow was monitored for 45 minutes. The
arrow represents the removal of Whatman filter paper saturated with 20% FeCl3).
Fig.10B: Box plots of the time of occlusion for the control mice treated with non-immune
IgG and for the mice treated with rat anti-mouse GPIb mabs. (The mean time of
occlusion for the control mice was 25 minutes. The error bars depict the range of the time
of occlusion for all six mice)

3.2. Platelet receptor GPIbα is required for stable thrombus formation in FeCl3
induced injury in mouse inferior vena cava
The data in Fig.10 demonstrate that FeCl3-induced occlusion of the IVC is platelet
dependent. Consequently, the role of the platelet specific receptor GPIb in FeCl3-induced
stable thrombus formation in the IVC was investigated because the requirement for GPIb
in venous (not venule) thrombosis has not been reported. In order to evaluate the
requirement of GPIb in thrombus formation in IVC, GPIb KO [21] mice were included in
this study. In agreement with the data reported in Fig.10A, the average time to occlusion

29

for WT mice in response to FeCl3 treatment was 27 mins. In contrast, no occlusion was
observed in any of the FeCl3 (N=6) treated GPIb KO mice (Fig. 11B),
(P =0.00006). Interpretation of these results was complicated by the fact that the GPIb
KO mice exhibit platelet deficiencies similar to those of Bernard-Soulier patients [21].
The GPIb KO mice have significantly lower than normal platelet count and the platelets
are larger than the normal platelets (macrothrombocytopenia) [21]. So to rule out the
possibility that the lack of occlusion in the GPIb KO mice was due to
macrothrombocytopenia rather than the GPIb deficiency, the response of mice that do not
express murine GPIb, but instead express the extracellular domain of the human
interleukin-4 receptor fused with the transmembrane and cytoplasmic domains of human
GPIb (IL-4R/GPIb-tg mice) was characterized [22]. Although these platelets lack the
extracellular domain of GPIb, they have the normal transmembrane and cytoplasmic
domains of human GPIb and therefore are normal in size and number. The IVCs of the
IL-4R/GPIb-tg mice failed to occlude (Fig.12A, bottom panel) (P = 0.00006), thereby
demonstrating that the extracellular domain of GPIb is required for stable thrombus
formation in response to FeCl3-induced injury of the IVC and possibly in veins, in
general.
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Fig.11A: 20% FeCl3-induced IVC injury to the WT mice (top panel) and GPIb KO mice
(bottom panel). (The arrow indicates the time of removal of the FeCl3 strip. Blood flow
was monitored for 45 minutes)
Fig.11B: Box plots of time of occlusion for control mice and GPIb KO mice. (The mean
time of occlusion for WT mice was 27 minutes).
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Fig.12A: 20% FeCl3-induced IVC injury to the WT mice (top panel) and IL-4R/GPIbα-tg
mice (bottom panel). (Blood flow was monitored for 45 minutes. The arrow indicates the
removal of FeCl3 strip after 10 minutes).
Fig.12B: Box plots of time of occlusion for control mice and IL-4R/GPIbα-tg mice.
(Mean time of occlusion for the WT mice was 27 minutes).

3.3. VWF is required for GPIb dependent thrombus formation in the mouse IVC.
The paradigm for FeCl3-induced arterial thrombosis is that the process is
mediated typically but not exclusively by GPIbα binding to VWF on the subendothelium
exposed by damage to the endothelium [8, 23]. The data presented in Figures 11B and
12B demonstrate that stable thrombus formation in the IVC resulting from FeCl3
treatment is GPIb dependent. But the requirement for VWF in this process has not been
reported. Accordingly, VWF deficient mice were evaluated in this system. The effect of
the absence of VWF was unambiguous, none of the 7 VWF KO inferior vena cavae
formed occlusive thrombi in response to FeCl3-induced injury (Fig. 13A). Seven VWF
+/- (heterozygote) mice were used as controls. Out of seven, five showed occlusion and
the remaining two showed a decrease in blood velocity but the injured IVCs did not
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occlude completely. Lack of thrombus formation in the VWF KO mice, demonstrates that
VWF is required for ferric chloride-induced thrombus formation under venous shear
rates.

Fig.13A: 20% FeCl3-induced IVC injury to the WT mice (top panel) and VWF KO mice
(bottom panel). (The arrow indicated the removal of FeCl3 strip after the 10 minutes
exposure. Blood flow was monitored for 45 minutes).
Fig.13B: Box plots of time of occlusion for the control mice and VWF KO mice. (The
mean time of occlusion for the WT mice was 30 minutes).

3.4. Histological and Immunohistological studies
Thrombi formed in response to the FeCl3-induced injury to the inferior vena cavae
were screened for the presence of platelets. In order to detect the presence of platelets in
the occluded vessel, transverse sections of the FeCl3 treated (20% FeCl3 for 10 minutes)
IVC was stained with Diffquick stain. Diffquick stains platelets a violet to purple color.
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m thick cross section of the control IVC treated with Diffquick stain.
Fig.14A: 5 µm
(Magnification: 10 X)
Fig.14B:: IVC treated with 20% FeCl3 for 10 minutes and then 0.5 µm
m thick cross sections
stained with Diffquick. (The arrows in Figure B indicate the violet to purple colored
platelets attached to the subendothelium and present in the thrombus).
(Magnification: 100 X)

Trans-sections
sections of the non
non-FeCl3 treated inferior vena cavae of the WT mice were
used as controls. As seen in Fig. 14B, violet to purple color stained platelets can be seen
attached to the subendothelium and also present in the throm
thrombus.. The presence of
platelets attached to the subendothelium support the first objective of the study by
demonstrating that platelets are involved in the initial step of the thrombus formation in
the IVC in response to FeCl3-induced injury.
Immunohistochemical
mical studies were also performed on the sections of an occluded
IVC previously treated with 20% FeCl3. Alternatively, antibodies specific for platelet
receptor GPIbα were used as a marker for platelets.
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m thick control IVC stained with the anti-GPIb antibody.
Fig.15A: 5 µm
(Magnification: 10 X)
m thick cross section of IVC treated with 20% FeCl3 for 10 minutes was
Fig.15B: 5 µm
stained with anti-GPIb
GPIb antibody. (Arrows in Figure 14B indicate the red colored platelets
in the thrombus and near the end
endothelium where injury was induced).
(Magnification: 100 X)

As seen in Fig.15A, the control IVC is clear after staining with anti-GPIbα
anti
antibody but red color stained platelets can be seen attached to the subendothelium and
are present in the thrombus form
formed in response to the FeCl3 treatment. Thus this supports
the hypothesis that platelets play a role in the thrombus formation in the IVC in response
to the FeCl3-induced
induced injury.
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CHAPTER 4: DISCUSSION
In this study, thrombus formation in the IVC of mice in response to FeCl3-induced
injury was characterized. The data demonstrated that FeCl3 induces thrombus formation
in the IVC and that thrombus formation in the IVC is platelet, platelet receptor GPIbα
and VWF dependent despite the presumptive low shear rate characteristic of the IVC.
Thrombus formation in high shear rate vessels such as arteries and arterioles is
platelet dependent and also requires the platelet receptor GPIbα [28]. The initial
interaction of GPIbα with its ligand VWF is required to form the layer of platelets that
adhere to the damaged vascular wall and provide the platelet foundation for further
thrombus growth [20]. The thoroughly characterized FeCl3-induced injury model was
used to study thrombus formation in arteries and arterioles [7, 30].
The mechanism of arterial thrombosis is considered to be essentially different
from the bases of thrombosis in veins [38]. Venous thrombus formation is thought to
occur on intact endothelia as a result of stasis, coagulation and fibrinolytic abnormalities,
inflammation of the endothelium and tissue factor activity [38]. Also, venous thrombi are
platelet-poor; and therefore some investigators feel that platelets are not required for the
thrombus formation at venous shear rates. But in vitro platelet adhesion experiments
using perfusion chambers have demonstrated platelet adhesion to immobilized
fibrinogen, fibrin and VWF at low shear rates [39]. In vitro studies have also shown slow
thrombus growth at low shear rates [13]. But in vivo studies characterizing the role of
platelets, GPIbα, and VWF at venous shear rates have not been reported and therefore
this study addresses this question. Previous studies were conducted on thrombus
formation in IVC in response to FeCl3 induced injury, but those studies did not measure
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the blood flow, instead they estimated the weight of the thrombi [33-35]. In contrast, the
data described here demonstrate that thrombus formation, even at low shear rates as in
IVC, in response to ferric chloride-induced injury requires platelets and GPIbα.
The platelet requirement for the thrombus formation in the IVC in response to
FeCl3 treatment was shown by using the mixture of rat anti-mouse GPIbα monoclonal
antibodies (mab), known to deplete platelets rapidly [33]. None of the six mice treated
with the mixture of mabs supported occlusion of the IVC after the FeCl3 treatment. This
demonstrated the requirement of platelets for thrombus formation at low shear rates.
Non-immune rat IgG was used as a control for the mab studies. Each FeCl3-treated
(IVC)/inferior vena cavae of the WT mice showed occlusion (n= 6, mean time of
occlusion= 25 minutes).
GPIb KO mice were used to evaluate the requirement of the platelet specific
receptor GPIbα, in thrombus formation at low shear rate. These GPIb KO mice are a
model of the human- Bernard Soulier syndrome. These mice exhibit
macrothrombocytopenia. The inferior vena cavae of all the eight GPIb KO mice failed to
occlude in response to FeCl3 treatment. Eight WT mice were used as controls and all of
their (IVC/)/inferior vena cavae treated with FeCl3 occluded (mean time of occlusion- 27
minutes). The lack of occlusion in the GPIb KO mice shows the requirement for this
platelet receptor in thrombus formation even at venous shear rates (50 s-1 to 100 s-1).
IL-4R/GPIbα-tg mice were studied to show the requirement of the extracellular domain
of GPIb, and thus to rule out the possibility that the lack of thrombus formation in GPIb
KO mice was due to the macrothrombocytopenia. The IL-4R/GPIbα-tg mice lack murine
GPIb, but have the extracellular domain of the human IL-4R fused with transmembrane
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and cytoplasmic domain of human- GPIb. The cytoplasmic domain of this chimeric
protein ameliorates the macrothrombocytopenia, but the protein still lacks the
extracellular domain of GPIbα. No occlusion was observed in each of the eight IL4R/GPIbα-transgenic mice IVC studied. In contrast, each FeCl3 treated IVC of the WT
mice showed occlusion (mean time= 27 minutes). So although previous studies have
shown that thrombus formation in response to ferric chloride-induced injury in venules
(shear rate- 150 s-1 to 200 s-1) is GPIbα independent [7], our data demonstrate and
confirm the requirement of the extracellular domain of GPIbα for thrombus formation
after ferric chloride treatment of the murine IVC.
VWF is the major ligand for the platelet receptor GPIb and their interaction is a
requirement for thrombus formation in high shear rate vessels [3]. But previous studies
carried out in high shear rate vessels such as arterioles, have found that the thrombus
formation after FeCl3-induced injury does not absolutely require VWF [8]. So we studied
the requirement for VWF in thrombus formation at venous shear rates. In vitro adhesion
studies have shown that platelets can adhere to VWF at low shear rates [9]. But the in
vivo requirement of VWF at venous shear rates in response to ferric chloride induced
injury had not been reported/characterized prior to our study. We used VWF KO mice to
study the thrombus formation in response to FeCl3-induced injury to the IVC. VWF +/mice were used as controls. Out of the seven VWF KO mice, none showed occlusion of
the IVC. In contrast all the WT mice occluded within 30 minutes (mean time of
occlusion). Thus our data demonstrate an absolute requirement of VWF for thrombus
formation in the IVC.
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Pulmonary embolism is the result of unstable thrombi in veins. Characterization
of thrombus formation in carotid arteries revealed stable GPIb/VWF dependent thrombus
formation in response to FeCl3-induced injury. Embolization did not occur throughout the
duration of observation period [30]. In contrast, thrombi in the occluded IVC embolized
frequently. This difference in stability of the thrombi formed in arteries and veins may be
the function of blood shear rate in veins and the physiological differences between
arteries and veins. But experiments testing this concept have not been done at the
physiological shear rates [40]. And so the reason for the embolization characteristic of the
venous thrombosis is not understood and remains unclear.
To summarize, our studies demonstrate that FeCl3-induced thrombus formation
occurs in the IVC of the mouse in a platelet, GPIb and VWF-dependent manner, despite
the large diameter and the venous shear rate of the IVC. These results support the
hypothesis that platelets can play an important role in DVT and VTE despite the low
shear rate characteristic of veins.
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CHAPTER 5: CONCLUSION
Thrombus formation in the mouse inferior vena cava in response to FeCl3induced injury was characterized. The thrombus formation in the inferior vena cava was
platelet, platelet-specific receptor GPIb and VWF dependent. This study demonstrated
that stable thrombus formation can occur in a large vein with a low shear rate in a
platelet, glycoprotein Ib-IX and VWF-dependent manner.
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CHAPTER 6: FUTURE SCOPE
The following next steps are required for this research:
1.

Thrombus formation in IVC in response to 20% FeCl3-induced injury

characterized in αIIbβ3 KO mice to study the importance of this receptor in thrombus
growth and stability at venous shear rates as being another important and abundant
receptor on the platelet membrane.
2.

Thrombus formation under more physiological conditions should be

characterized.
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